Hematopoietic stem cell transplant (HSCT) recipients are at high risk for opportunistic infections due to profound immunosuppression and graft-versus-host disease (GvHD). Molds and nontuberculous mycobacteria (NTM) pose diagnostic and therapeutic challenges, especially when infections overlap. A 42-year-old woman with prior allogeneic HSCT for acute myeloid leukemia (AML) developed pulmonary infections with Microascus spp. and Mycobacterium chimaera, later complicated by Aspergillus calidoustus and RSV infection. Initial therapy included voriconazole, amphotericin B, and a macrolide-based multidrug regimen for NTM. Modifications were required for drug resistance and hepatotoxicity. Despite partial response, recurrent fungal infection necessitated prolonged antifungal therapy, including adjunctive inhaled amphotericin B and terbinafine. Ultimately, progressive bronchiolitis obliterans prompted bilateral lung transplantation. Explant pathology revealed necrotizing granulomas positive for NTM and Microascus spp. Post-transplant prophylaxis with voriconazole, rifabutin, azithromycin, and inhaled amikacin prevented recurrence, and the patient remained clinically stable at 6-month follow-up. This case illustrates the complexity of managing overlapping mold and NTM infections in HSCT recipients, highlighting the need for individualized, multidisciplinary care. Therapeutic drug monitoring, careful adjustment for drug–drug interactions, and the use of adjunctive inhaled antifungals were critical to achieving a favorable outcome.
Background: Pulmonary nodular lymphoid hyperplasia is a rare benign lymphoproliferative disorder. Patients are commonly asymptomatic. Its radiological presentation is characterized by peripheral single nodular lesion, multiple nodules or mass-like consolidation. Therefore, it can mimic other more frequent pulmonary diseases, such as lung cancer and pulmonary lymphoma. The diagnosis is often late, relying on histopathological findings. Case Presentation: We report a case of a 66-year-old woman who presented with cough and upper respiratory tract symptoms. Chest CT revealed a mass in the right lower lobe, mediastinal and hilar enlarged lymph nodes and multifocal ground-glass and part solid nodules. PET-CT findings were concerning for primary lung malignancy. She underwent transbronchial needle aspiration biopsy of the enlarged lymph nodes and pulmonary mass. The results were negative for malignancy, but immunophenotyping by flow cytometry was concerning for a lymphoproliferative disorder. For this reason, a percutaneous CT-guided transthoracic core needle biopsy of the mass was performed. Immunophenotypic features of lymphoma were not identified. Overall findings were suggestive of nodular lymphoid hyperplasia. The follow-up chest CT showed near complete resolution of the mass with a residual ground-glass lesion and stability of the enlarged lymph nodes, ground-glass and part solid nodules. Conclusion: Pulmonary nodular lymphoid hyperplasia is an uncommon lung disorder, usually detected incidentally on chest imaging. Its radiological features can mimic lung cancer and other more prevalent pulmonary diseases. Therefore, a multidisciplinary approach, including histopathological confirmation is essential for an accurate diagnosis. Although rare, it should be considered in the differential diagnosis of pulmonary malignancies.